At what enterprise value was STERIMED acquired in 2025?

During the acquisition of STERIMED by IK PARTNERS in 2025, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of STERIMED when it was acquired by IK PARTNERS?

The exact EV/EBITDA multiple for STERIMED is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was STERIMED acquired by IK PARTNERS?

STERIMED was acquired by IK PARTNERS in 2025.

What was the revenue of STERIMED at the time of the deal?

The revenue of STERIMED at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the STERIMED acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the STERIMED deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/sterimed-signe-un-3e-buy-out-avec-ik-partners-2166904

← DATABASE

Home Database Healthcare & PharmaSTERIMED

04/2025

STERIMED acquired by IK PARTNERS

FRANCE Life Sciences / Medical Devices / Medical Consumables EV 500M - 1.5b EUR

Context

Sterimed completes its third buy-out (LBO) as IK Partners returns as the majority shareholder, taking over from Sagard. This transaction values the group at over EUR1 billion, a significant jump from its previous valuation. Under Sagard's ownership, Sterimed accelerated its international expansion, notably in North America and Asia. The new partnership with IK Partners aims to further consolidate the medical packaging market through a global buy-and-build strategy and to invest in sustainable, eco-friendly sterilization solutions.

Sagard had previously taken control of the company during an LBO in 2019.

STERIMED, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

A global leader in the manufacturing of medical sterilization packaging solutions. Sterimed designs, produces, and markets high-performance packaging materials (paper, film, and complex materials) used by medical device manufacturers and hospitals to maintain the sterility of instruments. The group operates several production sites worldwide (France, China, USA, Mexico).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2024

2023

Other operations with STERIMED

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
05/2026	STERIMED	SIMAGEC	FRANCE	Chemicals & Materials	The acquisition of Simagec by Sterimed is a strategic move to expand Sterimed's service offering to medical device manufacturers and pharmaceutical companies. The deal complements Sterimed's existing operations and enables the company to further strengthen its position in the medical packaging market. Simagec's expertise in rigid and flexible packaging solutions, contract packaging, and validation services will enhance Sterimed's capabilities and provide a more comprehensive range of services to its customers. The acquisition is also expected to accelerate Sterimed's strategic growth in the pharmaceutical industry, where Simagec has established a strong presence. The deal is a testament to Sterimed's commitment to innovation and growth, and is expected to drive long-term value creation for the company's shareholders. With the integration of Simagec, Sterimed will be able to leverage the combined expertise and capabilities of both companies to drive growth and expansion in the medical packaging market. The acquisition is also expected to provide new opportunities for Simagec's employees and customers, as part of a larger and more diversified company.
09/2019	SAGARD	STERIMED	FRANCE	Life Sciences	Sterimed, a global leader in medical sterilization packaging, has entered into exclusive negotiations with Sagard to organize a secondary LBO. This transaction facilitates the exit of Meeschaert Capital Partners, which held a majority stake since 2016 following the group's spin-off from ArjoWiggins. The current management team, led by CEO Thibaut Hyvernat, will remain significantly invested in this new chapter.

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of STERIMED by IK PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: sterimed

Acquirer: ik partners